Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation.

Abstract

Ischemic stroke risk in atrial fibrillation differs from patient to patient, depending on numerous variables. Many attempts have been made to translate this difference into simple numbers and to compare it to the hemorrhagic risk of anticoagulation. Different clinical scores have been studied to define a clear strategy. One score, the CHA2DS2-VASc score, has been extensively and successfully applied worldwide. Nevertheless, it is not yet the "perfect instrument". Many proposals have been made to integrate its clinical parameters with some biomarkers to improve its predictive power. This short review describes some of these biomarkers and their possible implications in potentiating the efficacy of clinical scores.

• Authors: Mario Piergiulio Pezzo, Antonella Tufano, Massimo Franchini
• Journal: Journal of clinical medicine (J Clin Med) Vol. 11 Issue 4 (Feb 09 2022) ISSN: 2077-0383 [Print] Switzerland
• PMID: 35207188 (Publication Type: Journal Article, Review)